[Intra-arterial chemotherapy in combination with radiotherapy for invasive bladder cancer and prostate cancer].

[Intra-arterial chemotherapy in combination with radiotherapy for invasive bladder cancer and prostate cancer].
复制标题

动脉内化疗联合放疗治疗浸润性膀胱癌和前列腺癌[J].

DOI:
--
复制
发表时间:
1999
期刊:
Hinyokika kiyo. Acta urologica Japonica
影响因子:
--
通讯作者:
H. Nakatsuji
H. Nakatsuji
中科院分区:
--
文献类型:
--
作者:
Y. Sumiyoshi;K. Hashine;H. Nakatsuji

文献摘要

被引文献

相似文献

回顾性研究了1979年9月至1990年3月间45例肌层浸润性膀胱癌患者,采用动脉内阿霉素化疗加低剂量放疗。28例(62%)患者达到完全缓解(CR),所有患者均可保留功能性膀胱。CR患者的10年病因特异性生存率为95.5%,但未达到CR的患者为39%。这些结果表明,在这种治疗达到CR的患者中,我们可能能够保留功能性膀胱。在一项前瞻性研究中,我们设计了一种新的动脉内化疗方案,以达到更高程度的有效性,并保留功能性膀胱。23例患者在完全经尿道切除术后同时接受吡拉西坦/顺铂动脉内化疗和放疗。21例(91%)患者达到CR。其中1例患者复发伴肺转移,并接受了手术治疗。2例未达到CR的患者死于癌症,21例患者存活,保留了功能性膀胱。对于前列腺癌的治疗,我们现在只对根治性前列腺切除术后的患者进行辅助动脉化疗加放疗。
Forty-five patients with muscle-invasive bladder cancer treated with intra-arterial doxorubicin chemotherapy plus low-dose radiotherapy between September 1979 and March 1990 were retrospectively studied. Twenty-eight (62%) patients achieved a complete response (CR) and in all of them, a functional bladder could be preserved. The 10-year cause-specific survival rate of patients with CR was 95.5%, but that of patients not achieving a CR was 39%. These results demonstrate that in patients who achieve a CR with this treatment, we may be able to preserve a functional bladder. In a prospective study, we designed a new intra-arterial chemotherapy regimen in order to achieve a higher degree of effectiveness and to preserve a functional bladder. Twenty-three patients were treated with concurrent pirarubicin/cisplatin intra-arterial chemotherapy and radiotherapy after complete transurethral resection. Twenty-one (91%) patients achieved CR. One of these patients had relapse with lung metastases and was treated surgically. Two patients who did not achieve a CR died of cancer, and 21 patients are alive with preservation of functional bladder. For treatment of prostate cancer, we now administer only adjuvant intra-arterial chemotherapy plus irradiation for patients after radical prostatectomy.